The Efficacy and Safety of Oral Propranolol for Infantile Hemangioma
Article Sidebar
Main Article Content
Abstract
Background: Infantile hemangioma (IH) is the most common benign tumor in children. The lesion is self-limited therefore the main treatment is observation but in complicated IH, oral propranolol is used with good result. The data for oral propranolol in the treatment of IH in Thailand is still limited.
Objectives: To evaluate the efficacy and safety of oral propranolol for IH
Methods: Cross-sectional study was performed in patient with IH (younger than 3- year-old) whom treated at Sisaket hospital from 1 July 2021 to 30 June 2022. The participants were treated with oral propranolol 2 mg/kg/day. The data was analyzed for the percentage reduction of the sizes of the lesions comparing before and after the treatment using the photograph base visual analog scales.
Result: There were 11 participants, male: female ratio 1:2.7, aged between 2-23 months (mean 10±8.7 months). 5 patients (45.5%) were preterm. The most common location of IH was the head and neck 8 patient (72.7%). All of patients responded to treatment. Duration of treatment was from 3-15 months (mean 10.6±3.3 months). No patients had rebound growth after stop the medication. No side effects were found. Response to the treatment was faster in the younger group than the older group (P<0.01)
Conclusion: Oral propranolol is a very effective treatment for IH with good response and few complications. It should be the first line treatment of IH and started early for better result.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics 2019;143(1):e20183475. doi: 10.1542/peds.2018-3475.
Anderson KR, Schoch JJ, Lohse CM, Hand JL, Davis DM, Tollefson MM Increasing incidence of infantile hemangiomas (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight. J Am Acad Dermatol 2016;74(1):120-6. doi: 10.1016/j.jaad.2015.08.024.
Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 2014;170(4):907-13. doi: 10.1111/bjd.12804.
Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131(1):128-40. doi: 10.1542/peds.2012-1691.
Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124(3):e423-31. doi: 10.1542/peds.2008-3458.
Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011;147(12):1371-6. doi: 10.1001/archdermatol.2011.203.
Sethuraman G, Yenamandra VK, Gupta V. Management of infantile hemangiomas: current trends. J Cutan Aesthet Surg 2014;7(2):75-85. doi: 10.4103/0974-2077.138324.
Techasatian L, Phukam N. Treatment Modalities and Outcomes of Infantile Hemangiomas at Srinagarind Hospital. J Med Assoc Thai 2016;99 Suppl 5:S74-80.
Smith CJF, Friedlander SF, Guma M, Kavanaugh A, Chambers CD. Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Res 2017;109(11):809-15. doi: 10.1002/bdr2.1023.
Callahan AB, Yoon MK. Infantile hemangiomas: A review. Saudi J Ophthalmol 2012;26(3):283-91. doi: 10.1016/j.sjopt.2012.05.004.
Ainipully AM, Narayanan SK, Vazhiyodan AP, Somnath P. Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome. J Indian Assoc Pediatr Surg 2019;24(3):170-5. doi: 10.4103/jiaps.JIAPS_12_18.
Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358(24):2649-51. doi: 10.1056/NEJMc0708819.
Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 2010;126(2):e418-26. doi: 10.1542/peds.2009-3166.
Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131(1):128-40. doi: 10.1542/peds.2012-1691.
Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 2004;26(3):309-14. doi: 10.1016/j.jemermed.2003.11.015.
Prey S, Voisard JJ, Delarue A, Lebbe G, Taïeb A, Leaute-Labreze C, et al. Safety of Propranolol Therapy for Severe Infantile Hemangioma. JAMA 2016;315(4):413-5. doi: 10.1001/jama.2015.13969.
Stringari G, Barbato G, Zanzucchi M, Marchesi M, Cerasoli G, Tchana B, et al. Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. Pediatr Med Chir 2016;38(2):113. doi: 10.4081/pmc.2016.113.
Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, et al. Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 2021;147(7):599-607. doi: 10.1001/jamaoto.2021.0454.
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015;372(8):735-46. doi: 10.1056/NEJMoa1404710.
Shah SD, Baselga E, McCuaig C, Pope E, Coulie J, Boon LM, et al. Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. Pediatrics 2016;137(4):e20151754. doi: 10.1542/peds.2015-1754.
